A Double-blind, Placebo-Controlled, Parallel-Group, Randomized, Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Effects of BMS-770767 in Subjects With Primary Hypercholesterolemia.
Latest Information Update: 08 Nov 2021
At a glance
- Drugs BMS 770767 (Primary)
- Indications Hypercholesterolaemia
- Focus Biomarker; Therapeutic Use
- 07 Apr 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 23 Mar 2011 Planned end date changed from 1 Apr 2011 to 1 Mar 2011 as reported by ClinicalTrials.gov.
- 02 Dec 2010 Additional trial location (USA) identified as reported by ClinicalTrials.gov.